Clinical Trials Browser

Phase 2 × Neoplasm Metastasis × efineptakin alfa × Clear all

NCT04984811 2024-03-05

NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis